therapeutics

Learn how recombinant antibody production uses genetic engineering to create highly specific antibodies, replacing traditional methods for therapeutic and diagnostic use.

Examine how CHO cell line development and optimized upstream processing improve therapeutic antibody production, ensuring high yields, consistent quality, and clinical efficacy.

Therapeutic antibody discovery begins with screening. Biointron applies ELISA, SPR, and AI-driven tools to identify high-affinity antibodies with precision and speed.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.

Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.

Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow, which can cause bone damage, anemia, kidney dysfunction, and weakened immunity. Despite being incurable, advances in antibody therapies have shown significant progress in the management of the disease, highlighting the ongoing efforts in the development of more effective treatments.

Learn about VHH antibodies, their history, diagnostic and therapeutic applications, and their role in advanced platforms like ELISA, biosensors, and targeted medicine.

Entering into the new year, the popularity of antibody-drug conjugates (ADCs) in the biopharma industry shows no signs of slowing down. In 2023, there were a record number of licensing partnerships in the ADC space, particularly Merck’s $22 billion deal with Daiichi Sankyo, Inc.

Combination antibody therapies enhance efficacy by targeting multiple pathways. Biointron showcases synergistic strategies that improve outcomes in cancer and infectious diseases.

Monoclonal antibodies fight antimicrobial resistance by targeting pathogens and complementing antibiotics. Learn how they expand the arsenal against AMR threats.

Cell signaling maps how life communicates. Explore pathways, cross-talk, and the antibody tools that reveal mechanisms behind immunity, cancer, and therapy.

Discover how antibody allotypes affect monoclonal antibody immunogenicity and performance, and learn how Biointron supports antibody discovery, engineering, and optimization.

Explore the benefits and limitations of monoclonal antibodies, including high specificity, broad research and clinical applications, production costs, and therapeutic challenges.

Explore the top 10 FDA-approved antibody drugs in 2023, including Humira, Keytruda, and Rituxan, and learn how Biointron supports antibody drug discovery and development.

Compare delivery options for antibody‑based therapies—conjugates, nanoparticles, liposomes, and long‑acting platforms—to improve exposure, precision, and patient safety.